Opportunity Information: Apply for RFA HG 22 019
The Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers funding opportunity (RFA HG 22 019) is a National Institutes of Health, NHGRI-led initiative that uses the cooperative agreement mechanism (U01; clinical trials not allowed) to stand up specialized centers focused on analyzing, validating, and making sense of data produced by the broader MorPhiC program. The central idea behind MorPhiC is to build a consistent, widely usable catalog of what happens in cells when individual human genes are fully knocked out (that is, when a gene has a null allele). Rather than looking at one gene or one disease at a time, MorPhiC is designed to systematically measure molecular and cellular consequences of gene loss across the genome using in vitro multicellular systems, then release those results as a community resource that other researchers can use for discovery, interpretation, and hypothesis generation.
Phase I is positioned as a practical, method-optimizing, proof-of-scale stage. In this first phase, the program plans to focus across a target set of about 1,000 protein-coding genes and work out how best to (1) generate null alleles reliably, (2) measure phenotypic effects in a consistent way across multiple sites and experimental systems, and (3) understand the real-world scaling limits of the approach. A major deliverable of Phase I is not only the initial dataset, but also the standards and infrastructure that make a larger effort feasible: shared data formats, clearer expectations for metadata and quality, and defined use cases describing how outside scientists should be able to query and interpret the catalog. Phase I is also explicitly meant to inform whether a later Phase II should happen and, if so, what it should look like in terms of scope, methods, and feasibility.
Within that larger structure, the Data Analysis and Validation (DAV) Centers are intended to serve as the computational and analytic backbone that helps ensure the resulting resource is credible, interpretable, and useful. These centers are expected to develop and apply computational models, data analysis pipelines, and visualization approaches that can evaluate data quality, validate signals, and support cross-gene and cross-system comparisons. In practice, that implies work such as establishing reproducible processing workflows, defining and applying QC metrics, identifying batch effects and technical artifacts, supporting integration of multi-omic or multi-modal readouts when applicable, and building analysis approaches that can translate raw assay outputs into interpretable molecular and cellular phenotype summaries. The emphasis on validation and utility means these centers are not just doing downstream statistics; they are helping shape how data are assessed, compared, and presented so that the final catalog can actually be used with confidence by the broader biomedical community.
Administratively, this opportunity is categorized as discretionary funding in the health area, under CFDA 93.172, and uses a U01 cooperative agreement, which generally signals substantial NIH program involvement and coordination across awardees. The FOA lists an award ceiling of $350,000 and an original closing date of 2022-11-01. The applicant pool is intentionally broad, spanning many types of domestic institutions and organizations, including state and local governments, public and private institutions of higher education, independent school districts, special district governments, federally recognized Native American tribal governments, and public housing authorities/Indian housing authorities. It also includes nonprofit organizations (with and without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses. The eligibility language also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, US territories or possessions, and even non-US entities (foreign organizations), underscoring a desire to draw expertise from a wide range of settings.
Taken together, the opportunity is best understood as funding for advanced analytic centers that will collaborate closely with other MorPhiC components to make a first large-scale, standardized reference of gene knockout phenotypes possible. The DAV Centers role is to help turn complex experimental outputs into a coherent, validated, and accessible catalog, while also helping define the standards, formats, and analysis practices that will determine whether MorPhiC can scale beyond Phase I into a broader, genome-wide resource.Apply for RFA HG 22 019
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation Centers (U01 Clinical trials not allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2022-08-11.
- Applicants must submit their applications by 2022-11-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: MorPhiC Phase I - Data Analysis and Validation (DAV) Centers (RFA HG 22 019)
What is this funding opportunity?
This opportunity funds Molecular Phenotypes of Null Alleles in Cells (MorPhiC) Phase I: Data Analysis and Validation (DAV) Centers under RFA HG 22 019. It is a National Institutes of Health (NIH), NHGRI-led initiative using a U01 cooperative agreement (clinical trials not allowed) to create specialized centers that analyze, validate, and interpret data generated by the broader MorPhiC program.
What is MorPhiC trying to accomplish overall?
MorPhiC aims to build a consistent, widely usable catalog describing what happens in cells when individual human genes are fully knocked out (null alleles). Instead of focusing on one gene or one disease at a time, the program is designed to systematically measure molecular and cellular consequences of gene loss across the genome using in vitro multicellular systems and release the results as a community resource for discovery and hypothesis generation.
What does it mean that MorPhiC focuses on "null alleles"?
In this context, a null allele means a gene is fully knocked out so that its function is lost. MorPhiC is centered on observing and cataloging the cellular and molecular outcomes of that complete loss of gene function.
What is Phase I, and why does it exist?
Phase I is the program's practical, method-optimizing, proof-of-scale stage. It is intended to test and refine approaches, establish standards, and assess real-world scaling limits. Phase I is meant to inform whether a later Phase II should occur and, if so, what its scope, methods, and feasibility should be.
How many genes are targeted in Phase I?
Phase I plans to focus on a target set of about 1,000 protein-coding genes.
What are the main technical goals of Phase I?
Phase I is expected to determine how best to: (1) generate null alleles reliably, (2) measure phenotypic effects consistently across multiple sites and experimental systems, and (3) understand practical scaling limits of the overall approach.
What are the key deliverables of Phase I?
Phase I deliverables include both the initial dataset and the standards/infrastructure needed to support a larger effort. The description emphasizes shared data formats, clearer expectations for metadata and quality, and defined use cases explaining how outside scientists should be able to query and interpret the catalog.
What is a Data Analysis and Validation (DAV) Center in this program?
DAV Centers are intended to be the computational and analytic backbone of MorPhiC Phase I. Their role is to help ensure the resulting resource is credible, interpretable, and useful by developing and applying computational models, analysis pipelines, and visualization approaches that evaluate data quality, validate signals, and support comparisons across genes and experimental systems.
What kinds of work are DAV Centers expected to do?
Based on the opportunity description, DAV Centers are expected to perform work such as establishing reproducible processing workflows, defining and applying quality control (QC) metrics, identifying batch effects and technical artifacts, supporting integration of multi-omic or multi-modal readouts when applicable, and translating raw assay outputs into interpretable molecular and cellular phenotype summaries.
Are DAV Centers only doing "downstream statistics" after experiments are finished?
No. The emphasis on validation and utility suggests DAV Centers are not limited to downstream statistical analysis. They are also expected to help shape how data are assessed, compared, and presented so the final catalog can be used with confidence by the broader biomedical community.
How do DAV Centers fit into the broader MorPhiC program structure?
DAV Centers collaborate closely with other MorPhiC components and focus on turning complex experimental outputs into a coherent, validated, and accessible catalog. They also contribute to defining standards, formats, and analysis practices that influence whether the program can scale beyond Phase I.
What funding mechanism is used for this opportunity?
The program uses a U01 cooperative agreement mechanism, and the description notes that this generally signals substantial NIH program involvement and coordination across awardees.
Are clinical trials allowed under this funding mechanism?
No. The opportunity is specified as U01; clinical trials not allowed.
Which NIH institute is leading this effort?
The initiative is NIH and NHGRI-led (National Human Genome Research Institute).
What is the award ceiling listed in the FOA?
The FOA lists an award ceiling of $350,000.
What was the original closing date for this opportunity?
The original closing date listed is 2022-11-01.
How is the opportunity categorized administratively?
It is described as discretionary funding in the health area under CFDA 93.172.
Who is eligible to apply?
The eligibility described is intentionally broad and includes many types of domestic institutions and organizations, such as state and local governments, public and private institutions of higher education, independent school districts, special district governments, federally recognized Native American tribal governments, and public housing authorities/Indian housing authorities.
Are nonprofits eligible?
Yes. Nonprofit organizations are included, both with and without 501(c)(3) status.
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are included, and small businesses are also listed as eligible.
Are minority-serving and mission-specific institutions explicitly included?
Yes. The eligibility language explicitly highlights Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, and faith-based or community-based organizations.
Are regional organizations and U.S. territories mentioned as eligible?
Yes. Regional organizations and U.S. territories or possessions are specifically mentioned in the eligibility language.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility language includes non-U.S. entities (foreign organizations), indicating the program is open to expertise from a wide range of settings.
What is the main value proposition of funding DAV Centers?
The opportunity is best understood as support for advanced analytic centers that help make a first large-scale, standardized reference of gene knockout phenotypes possible. DAV Centers help ensure the catalog is validated, interpretable, and accessible, and they help define the analysis and data standards that influence the program's ability to scale in the future.
What kinds of outputs are DAV Centers expected to improve for end users?
The description emphasizes outputs that improve credibility and usability, including validated signals, consistent QC and artifact detection, cross-gene and cross-system comparisons, visualization approaches, interpretable phenotype summaries, and standards such as shared data formats, metadata expectations, and defined use cases for how outside scientists can query and interpret the catalog.
Browse more opportunities from the same category: Health
Next opportunity: Pediatric Scientist Development Program (PDSP) (K12 Clinical Trial Not Allowed)
Previous opportunity: Regenerative Medicine Innovation Projects (RMIP) Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 22 019
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 22 019) also looked into and applied for these:
| Funding Opportunity |
|---|
| Advancing Health and Malaria Services Apply for 72068522RFA00001 Funding Number: 72068522RFA00001 Agency: Senegal USAID-Dakar Category: Health Funding Amount: $39,500,000 |
| AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed) Apply for PAR 22 221 Funding Number: PAR 22 221 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Javits Neuroscience Investigator Award Extension Request (Type 4 Clinical Trial Optional) Apply for PAR 23 022 Funding Number: PAR 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional) Apply for PAR 22 228 Funding Number: PAR 22 228 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fostering Mental, Emotional, and Behavioral (MEB) Health Among Children in School Settings: Opportunities for Multisite Trials of Complementary and Integrative Health Interventions (Clinical Trial Optional) Apply for RFA AT 23 003 Funding Number: RFA AT 23 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Research Resource Center to Build an Open-Access Repository and Database for Anatomical and Physiological Correlates of Acupoints (U24, Clinical Trial Optional) Apply for RFA AT 23 005 Funding Number: RFA AT 23 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| FY 2023 AmeriCorps State and National Public Health AmeriCorps Grants Apply for AC 08 20 22 Funding Number: AC 08 20 22 Agency: AmeriCorps Category: Health Funding Amount: Case Dependent |
| Practice-Based Research Integrating Multidisciplinary Experiences in Dental Schools (PRIMED) (U01 Clinical Trial Not Allowed) Apply for RFA DE 23 012 Funding Number: RFA DE 23 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Conference Grant Programs (R13) Apply for PA 22 238 Funding Number: PA 22 238 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $50,000 |
| Maintaining Immunity after Immunization (U01 Clinical Trial Not Allowed) Apply for RFA AI 22 055 Funding Number: RFA AI 22 055 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| REsearch Across Complementary and Integrative Health Institutions (REACH) Virtual Resource Centers (U24 Clinical Trial Not Allowed) Apply for RFA AT 23 007 Funding Number: RFA AT 23 007 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Optimization of Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (U01 - Clinical Trials Not Allowed) Apply for RFA NS 23 017 Funding Number: RFA NS 23 017 Agency: National Institutes of Health Category: Health Funding Amount: $650,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurship Enhancement Award (R25 Independent Clinical Trial Not Allowed) Apply for PAR 22 226 Funding Number: PAR 22 226 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed) Apply for PAR 22 227 Funding Number: PAR 22 227 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed) Apply for PAR 22 235 Funding Number: PAR 22 235 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed) Apply for PAR 23 027 Funding Number: PAR 23 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ National Research Service Award (NRSA) Institutional Research Training Grant (T32) Apply for RFA HS 22 010 Funding Number: RFA HS 22 010 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Understanding the Supply of Professional Dementia Care Providers and Their Decisions (U54 Clinical Trial Not Allowed) Apply for RFA AG 23 018 Funding Number: RFA AG 23 018 Agency: National Institutes of Health Category: Health Funding Amount: $16,200,000 |
| Development of Animal Models and Related Materials for HIV/AIDS Research (R24 Clinical Trials Not Allowed) Apply for PAR 22 204 Funding Number: PAR 22 204 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed) Apply for RFA OD 22 013 Funding Number: RFA OD 22 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 22 019", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.